BCKDK

BCKDK is a mitochondria-associated serine/threonine kinase that controls branched-chain amino acid (BCAA) catabolism by phosphorylating and inactivating the E1α subunit of the branched-chain α-keto acid dehydrogenase complex (BCKDH), and also phosphorylates the pyruvate dehydrogenase complex when canonical PDK kinases are absent (PMID:24449431, PMID:33773101). Beyond metabolic regulation, BCKDK phosphorylates diverse non-metabolic substrates—including MEK, BCAT1, STUB1, RNF8, BCLAF1, and the chromatin remodeling factor Phf10/Baf45a—thereby engaging MAPK/ERK signaling, DNA homologous recombination repair, MYC-driven glycolysis, and zygotic genome activation (PMID:28501528, PMID:38621458, PMID:40298908, PMID:40442441, PMID:41254269). BCKDK activity and stability are regulated by upstream tyrosine kinases Src (at Y246) and Fyn (at Y151) and by opposing ubiquitin-mediated turnover through TRIM21 and the deubiquitinase PSMD14, while the E3 ligase UBE3B also targets BCKDK as an in vivo substrate (PMID:32238881, PMID:39170503, PMID:41876842, PMID:30808755). Loss-of-function mutations in BCKDK cause a Mendelian disorder characterized by reduced plasma BCAAs with increased BCKDH activity, and BCKDK deficiency additionally disrupts mitochondrial Complex I stability, bioenergetics, and dynamics (PMID:24449431, PMID:26809120, PMID:39709505).

1. 2014 High

   Establishing the core enzymatic function: patient loss-of-function mutations demonstrated that BCKDK is the kinase responsible for phosphorylating and inactivating BCKDH-E1α, defining its role as the master negative regulator of BCAA catabolism.

   Evidence Biochemical analysis of patient-derived fibroblasts with BCKDK mutations showing undetectable phospho-E1α and increased BCKD activity

   PMID:24449431

   Open questions at the time

   • Structural basis for E1α recognition not resolved
   • Whether BCKDK has additional mitochondrial substrates was unknown
2. 2016 Medium

   BCKDK deficiency was shown to impair mitochondrial bioenergetics and dynamics, revealing that the kinase's function extends beyond substrate-level metabolic regulation to maintenance of respiratory chain function and mitochondrial morphology.

   Evidence Oxygen consumption, ATP, ROS, and electron microscopy in BCKDK-deficient patient fibroblasts with knockdown recapitulation

   PMID:26809120

   Open questions at the time

   • Direct mitochondrial target(s) mediating bioenergetic and morphological changes were not identified
   • Whether the effect is secondary to BCAA imbalance was not excluded
3. 2017 Medium

   The discovery that BCKDK directly phosphorylates MEK to activate ERK signaling in colorectal cancer established the first non-metabolic substrate and linked BCKDK to oncogenic MAPK pathway activation.

   Evidence Co-immunoprecipitation, MEK phosphorylation western blot, and cell transformation assays with pharmacological inhibition

   PMID:28501528

   Open questions at the time

   • Specific MEK phosphorylation site not mapped
   • Independence from BCAA effects inferred but not fully dissected genetically
4. 2019 Medium

   Identification of BCKDK as an in vivo substrate of the E3 ligase UBE3B revealed that BCKDK protein levels are controlled by ubiquitin-dependent degradation, connecting its regulation to Kaufman oculocerebrofacial syndrome-associated metabolic perturbations.

   Evidence Proteomics-based substrate identification and metabolomic profiling in Ube3b-knockout mice

   PMID:30808755

   Open questions at the time

   • Specific ubiquitination sites on BCKDK by UBE3B not mapped
   • Functional consequence of UBE3B loss on BCKDK activity not directly measured
5. 2020 High

   Src and APN-mediated phosphorylation of BCKDK at Y246 and S31, respectively, established that BCKDK is itself subject to upstream kinase regulation that modulates both its catalytic activity and its engagement with ERK signaling.

   Evidence In vitro kinase assays, phosphoproteomics, Src-KO validation, point mutation analysis, and proximity ligation assay

   PMID:32238881 PMID:32457292

   Open questions at the time

   • Whether Y246 and S31 phosphorylation are coordinated or independent events is unknown
   • The phosphatase(s) opposing these modifications are unidentified
6. 2021 High

   Genetic epistasis in mice revealed BCKDK as a compensatory kinase for the pyruvate dehydrogenase complex (PDC) when all four PDK isoforms are absent, demonstrating substrate promiscuity with developmental significance.

   Evidence Sequential Pdk1-4 knockout combined with Bckdk knockout in mice; PDC phosphorylation and metabolic flux analysis

   PMID:33773101

   Open questions at the time

   • Whether BCKDK phosphorylates PDC under physiological conditions with PDKs present is unclear
   • Specific PDC subunit phosphorylation sites targeted by BCKDK not fully resolved
7. 2021 Medium

   BCKDK silencing reduced mitochondrial electron transport chain protein expression, oxygen consumption, and mTORC1 signaling in breast cancer cells, reinforcing a broader role in mitochondrial and growth-regulatory homeostasis beyond BCAA catabolism.

   Evidence Genetic knockdown and pharmacological inhibition with transcriptomics, OCR, and mTORC1 pathway readouts in TNBC cells

   PMID:34526485

   Open questions at the time

   • Direct versus indirect effects on ETC complex expression not distinguished
   • Whether sestrin 2 upregulation is a direct phosphorylation target or transcriptional response is unknown
8. 2023 High

   BCKDK was shown to phosphorylate both BCAT1 (enhancing its activity) and STUB1 (disrupting BCAT1 ubiquitination), revealing a dual mechanism of substrate stabilization through direct phosphorylation and E3 ligase interference.

   Evidence In vitro kinase assays, mass spectrometry-based site mapping, point mutation analysis, and in vivo tumor models

   PMID:38621458

   Open questions at the time

   • Whether the BCAT1-stabilizing mechanism operates outside glioblastoma contexts is untested
   • Crystal structure of BCKDK–BCAT1 interaction lacking
9. 2023 Medium

   BCKDK was found to stabilize talin1 by blocking TRIM21-mediated ubiquitination, linking BCKDK to integrin-associated FAK/MAPK signaling and cell migration—expanding its non-catalytic scaffolding functions.

   Evidence Co-immunoprecipitation, ubiquitination assays, migration assays in vitro and lung metastasis in vivo

   PMID:37460470

   Open questions at the time

   • Whether BCKDK directly phosphorylates talin1 or acts purely as a competitive binding partner for TRIM21 is unresolved
   • Single-lab finding without independent replication
10. 2024 Medium

    Multiple studies expanded the BCKDK substrate repertoire and regulatory network: Fyn phosphorylates BCKDK at Y151 in glioblastoma; BCKDK interacts with and stabilizes NDUFS1 of Complex I to maintain mitochondrial membrane potential; nuclear BCKDK phosphorylates RNF8 to facilitate homologous recombination repair; BCKDK stabilizes G6PD to promote the pentose phosphate pathway; PSMD14 deubiquitinates BCKDK opposing TRIM21; and BCKDK phosphorylates BCLAF1 to activate MYC transcription.

    Evidence Kinase assays, Co-IP, subcellular fractionation, ChIP, isotope tracing, deubiquitination assays, iPSC-derived neuron models, and tumor models across multiple independent studies

    PMID:39025830 PMID:39170503 PMID:39709505 PMID:40298908 PMID:40442441 PMID:41876842

    Open questions at the time

    • Most non-metabolic substrates identified in single labs without independent replication
    • Structural basis for BCKDK's nuclear localization signal not identified
    • Relative physiological importance of metabolic versus non-metabolic BCKDK functions is unranked
11. 2025 High

    BCKDK was shown to phosphorylate the chromatin remodeling factor Phf10/Baf45a in zebrafish, establishing an essential role during the maternal-to-zygotic transition through regulation of zygotic genome activation and miR-430 processing.

    Evidence CRISPR-RfxCas13d maternal knockdown screen, phospho-proteomics, genetic epistasis, and phospho-mimetic rescue in zebrafish embryos

    PMID:41254269

    Open questions at the time

    • Whether the BCKDK–Phf10 axis is conserved in mammals is unknown
    • Mechanism by which Phf10 phosphorylation controls miR-430 processing not fully elucidated

• A unifying structural and systems-level understanding of how BCKDK achieves substrate selectivity across its diverse metabolic and non-metabolic targets, and how its mitochondrial, cytoplasmic, and nuclear pools are differentially regulated, remains to be established.
• No crystal or cryo-EM structure of full-length BCKDK bound to non-BCKDH substrates
• Relative contribution of BCKDK kinase activity versus scaffolding to each phenotype not systematically tested
• How BCKDK is partitioned among subcellular compartments is mechanistically unresolved